ALK-Abelló (Germany)

ALK-Abelló (Germany)

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for ALK-Abelló (Germany), Germany, covering academic research published from 2001 to 2024. Read More.


Open Access Percentage

53%


Total
Publications

95


Total Open
Publications

50


Total
Citations

3.4K


Open Access
Percentage

53%


Total
Publications

95


Total Open
Publications

50


Total
Citations

3.4K

Wikipedia

Website

download

Breakdown

26% 16% 8% 50%

Publisher Open

26%

Both

16%

Other Platform Open

8%

Closed

50%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0123456789Total Publications
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

33%OA Journal

OA Journal 33%

12

Hybrid 16%

6

No Guarantees 51%

19

Other Platform Open

Domain 57%

12

Institution 43%

9

Other Internet 19%

4

Preprint 0%

0

Public 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
12
Unknown Repository
Other Internet
3
Utrecht University - Utrecht University Repository
Institution
1
Universität Bielefeld - Publikationen an der Universität Bielefeld
Institution
1
University of Turin - Institutional Research Information System University of Turin
Institution
1
Universidad Politécnica de Madrid - Archivo Digital UPM
Institution
1
Universidad del Pais Vasco - Communities in ADDI
Institution
1
Site cant be reached
Institution
1
Scientific periodicals of Ukraine
Institution
1
Leibniz Universität Hannover - Institutional Repository of Leibniz Universität Hannover
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share